Last reviewed · How we verify
MM-II dose III
At a glance
| Generic name | MM-II dose III |
|---|---|
| Sponsor | Sun Pharmaceutical Industries Limited |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer (PHASE3)
- Ultrasound IPP to Predict Response to Medical Therapy in LUTS/BPH
- Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features (PHASE2, PHASE3)
- Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults (PHASE2, PHASE3)
- Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis (PHASE2)
- Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma (PHASE2)
- A Phase Ib Study of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02) (PHASE1)
- Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MM-II dose III CI brief — competitive landscape report
- MM-II dose III updates RSS · CI watch RSS
- Sun Pharmaceutical Industries Limited portfolio CI